The mA Reader YTHDF1 Promotes Lung Carcinoma Progression via Regulating Ferritin Mediate Ferroptosis in an mA-Dependent Manner.

Pharmaceuticals (Basel)

Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Published: January 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

N6-methyladenosine (mA) plays a significant role as an epigenetic mechanism, which is involved in various cancers' progress via regulating mRNA modification. As a crucial mA "reader", YTHDF1 is able to alter mA-modified mRNA and promote the protein translation process in multiple cancers. However, the role of YTHDF1 in lung cancer has not been fully investigated. This study focuses on elucidating the function of YTHDF1 in the development of lung cancer and its underlying mechanism. We demonstrated that YTHDF1 was highly expressed in lung carcinoma progression; then, the loss of function experiments in lung cell lines confirmed that knockdown of YTHDF1 suppressed cell proliferation, migration and invasion and induced ferroptosis of lung cancer cells. Further functional assays showed that ferritin (FTH) was identified as the key target of YTHDF1 in lung cancer cells. Furthermore, the overexpression of ferritin in YTHDF1-depleted cells partially restored lung cancer cell suppression. Collectively, our data suggested that the upregulation of YTHDF1 promotes lung cancer carcinogenesis by accelerating ferritin translation in an mA-dependent manner. We hope that our findings may provide a new target for lung cancer diagnosis and treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966794PMC
http://dx.doi.org/10.3390/ph16020185DOI Listing

Publication Analysis

Top Keywords

lung cancer
28
lung
10
ythdf1 promotes
8
promotes lung
8
lung carcinoma
8
carcinoma progression
8
ma-dependent manner
8
ythdf1 lung
8
cancer cells
8
ythdf1
7

Similar Publications

Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.

View Article and Find Full Text PDF

Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.

JCO Precis Oncol

September 2025

Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart

View Article and Find Full Text PDF

Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).

View Article and Find Full Text PDF